Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

181.52 -0.42 (-0.23%)
Streaming Delayed Price Updated: 10:01 AM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
56 57 Next >
News headline image
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies ↗
 
Via Benzinga
News headline image
Does This Signal Trouble for Biogen's New Alzheimer's Drug? ↗
Biogen is counting on Leqembi to boost its revenue growth. 
Via The Motley Fool
News headline image
How to Retire Rich: Biotech Stocks Edition ↗
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks. 
Via InvestorPlace
News headline image
2 Market-Beating Stocks With Major Catalysts on the Way ↗
Can these companies keep climbing? 
Via The Motley Fool
News headline image
7 Undervalued S&P 500 Stocks to Buy in June ↗
If you want to maximize your upside potential in a relatively predictable arena, these undervalued S&P 500 stocks could be for you. 
Via InvestorPlace
News headline image
Expert Ratings for Biogen ↗
 
Via Benzinga
News headline image
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed ↗
Senator Bernie Sanders vowed to oppose President Joe Biden's nominated candidate, Monica Bertagnolli, or any other current or future health agency nominee, to lead the National Institutes of Health... 
Via Benzinga
News headline image
Why Biogen Stock Is Trading Down Today ↗
Biogen Inc. (NASDAQ: BIIB) shares fell Tuesday after it was deemed that the ability of the company's Alzheimer's drug, Leqembi, to slow cognitive decline may not outweigh its risks, according to... 
Via Benzinga
News headline image
Methode Electronics, Brookfield Renewable Partners And Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded higher, with the Dow Jones rising around 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources ↗
Experts in Europe considering the potential use of a new Alzheimer's disease drug developed by Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) say Leqembi (lecanemab)'s ability to slow 
Via Benzinga
News headline image
Biogen Announces Changes to Its Board of Directors
From Biogen Inc.
Via GlobeNewswire
News headline image
Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground ↗
For the bull run to continue we need broader market participation from SMID caps. 
Via Talk Markets
News headline image
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote ↗
Friday, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that the data from Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) Phase 3 Clarity AD tria 
Via Benzinga
News headline image
Why Are Cruise Stocks CCL, RCL, NCLH Up Today? ↗
Cruise stocks are on the rise Monday as investors react to a positive note to clients from JPMorgan analysts and we've got the details! 
Via InvestorPlace
News headline image
BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing ↗
Biogen (BIIB) stock is a hot topic among traders Monday as the company's share resumed trading following a halt that was in effect on Friday. 
Via InvestorPlace
News headline image
Nasdaq, S&amp;P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low ↗
 
Via Benzinga
News headline image
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment ↗
A panel of experts will debate the merits of Biogen's drug, Leqembi. 
Via Investor's Business Daily
News headline image
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable' ↗
Senator Bernie Sanders urged the U.S. 
Via Benzinga
News headline image
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval ↗
FDA Peripheral and Central Drugs Advisory Committee is meeting Friday (June 9) to discuss a supplemental marketing application for Leqembi (lecanemab) submitted by Eisai Co Ltd (OTC: ESALY) for... 
Via Benzinga
News headline image
Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near ↗
The FDA's advisors will consider the full approval of Leqembi on Friday. 
Via Investor's Business Daily
News headline image
Thinking Of Buying Boston Properties? Here Are The Properties And Tenants You'd Add To Your Portfolio ↗
When investors consider the purchase of a real estate investment trust (REIT), along with performance and dividends, they need to consider the properties and tenants that accompany that REIT. Several... 
Via Benzinga
News headline image
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure ↗
 
Via Benzinga
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
News headline image
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump ↗
The news also benefits Biogen's partner Eisai and rival Eli Lilly. 
Via Investor's Business Daily
News headline image
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run ↗
Shares surged into and out of the company's R&D Day, which included a surprise. 
Via Investor's Business Daily
News headline image
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption? ↗
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers. 
Via Talk Markets
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.